Simultaneous analyses of urinary eicosanoids and related mediators identified tetranor-prostaglandin E metabolite as a novel biomarker of diabetic nephropathy

• Published in: Journal of lipid research Vol. 62; p. 100120
• Main Authors: Morita, Yoshifumi, Kurano, Makoto, Sakai, Eri, Sawabe, Motoji, Aoki, Junken, Yatomi, Yutaka
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2021; American Society for Biochemistry and Molecular Biology; Elsevier
• Subjects: arachidonic acid; Biomarkers - urine; clinical stages; Diabetic Nephropathies - urine; diabetic nephropathy; Eicosanoids; Eicosanoids - metabolism; Eicosanoids - urine; Humans; LC-MS/MS; leukotriene B4-ethanolamide; maresin-1; Patient-oriented and Epidemiological Research; Prostaglandins E, Synthetic - metabolism; Prostaglandins E, Synthetic - urine; solid-phase extraction; tetranor-PGEM; urine; arachidonic acid; urine; ROC; Eicosanoids; LT; MRM; SPE; DN; COX; OPLS; maresin-1; AUC; leukotriene B4-ethanolamide; LC-MS/MS; clinical stages; GFR; CV; solid-phase extraction; CSF; PG; tetranor-PGEM; AEA; diabetic nephropathy
• ISSN: 0022-2275; 1539-7262; 1539-7262
• DOI: 10.1016/j.jlr.2021.100120

Diabetic nephropathy is a major complication of diabetes mellitus, and thus novel biomarkers are desired to evaluate the presence and progression of diabetic nephropathy. In this study, we sought to identify possible metabolites related to diabetic nephropathy among urinary eicosanoids and related mediators. Using liquid chromatogram-tandem mass spectrometry, we optimized the lipid extraction from urine using the Monospin C18 as a solid-phase extraction cartridge and measured the urinary lipid mediators in 111 subjects with type 2 diabetes mellitus as well as 33 healthy subjects. We observed that 14 metabolites differed significantly among the clinical stages of nephropathy. Among them, levels of tetranor-prostaglandin E metabolite (tetranor-PGEM), an arachidonic acid metabolite, were significantly higher in subjects with stage 1 nephropathy than in healthy subjects and increased with the progression of nephropathy. We also observed that levels of maresin-1, a docosahexaenoic acid metabolite, and leukotriene B4-ethanolamide, an arachidonoyl ethanolamide metabolite, were significantly lower in subjects with stage 3–4 nephropathy than in healthy subjects and those with stage 1–2 nephropathy. Finally, using a comprehensive analysis of urinary eicosanoids and related mediators, we concluded that tetranor-PGEM was capable of discriminating clinical stages of nephropathy and thus useful as a novel biomarker for diabetic nephropathy.